Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Alzheimer disease

April 21, 2023 CD as API / Pharma applications

The review article ‘Molecular Mind Games’ describes the latest developments in cyclodextrin research for the treatment of brain disorders

The human brain is a complex and intricate network of cells and molecules that control every aspect of our behaviour

Continue reading

February 16, 2023 Drug delivery / Pharma applications

Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach

Neurodegeneration is characterized by progressive, disabling, and incurable neurological disorders with the massive loss of specific neurons. As one of

Continue reading

December 1, 2022 CD as API / Pharma applications

Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?

In this review, based on 250 references, the general chemical principles of direct cyclodextrin–protein interactions are summarized and highlighted, through

Continue reading

November 10, 2022 CD as API / Food / Pharma applications

Beer to prevent Alzheimer Disease

Beer is one of the oldest and most popular beverages in the world. Its bitter taste comes from the hops

Continue reading

August 3, 2022 CD as API / Pharma applications

HPaCD against Alzheimer Disease

HP-beta-cyclodextrin (HPbCD) is currently in clinical trials against Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease (AD) and these trials

Continue reading

July 25, 2022 Drug delivery / Pharma applications

SBEβCD-based nanodelivery system targeting the brain

Neuroinflammation occurs early in Alzheimer’s disease (AD). The initial stage of AD is related to glial dysfunction, which contributes to

Continue reading

July 12, 2022 CD as API / Events / Pharma applications

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator

Continue reading

August 25, 2021 Drug delivery / Pharma applications

Nasal powders of quercetin-β-cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation

Quercetin, a flavonoid with possible neuroprotective action has been recently suggested for the early-stage treatment of Alzheimer’s disease. The low

Continue reading

July 30, 2021 CD as API / Pharma applications

Cyclo Therapeutics Inc. Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™

On July 27, the Cyclo Therapeutics, a clinical stage biotechnology firm dedicated to developing life-changing medicines through science and innovation

Continue reading

May 20, 2021 Drug delivery / Pharma applications

Sevoflurane may affect tau spread in the brain to promote Alzheimer’s disease pathology

According to the press release of Massachusetts General Hospital sevoflurane may induce changes in the brain leading to Alzheimer disease.

Continue reading

Posts navigation

1 2 Next Posts»

Recent Posts

  • Crystallization inhibition by methylated cyclodextrin
  • Alfa-cyclodextrin MS-signals from Danish Golden Age paintings
  • The mechanism and therapy of aortic aneurysms
  • Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated colitis in mice
  • A review on Sulfobutylether-β-cyclodextrin for drug delivery applications

Tags

alpha-CD Alzheimer disease Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (15)
  • Analysis (37)
  • CD as API (215)
  • CD derivatives (269)
  • Cosmetics and toilettry (22)
  • Diagnosis (1)
  • Drug delivery (461)
  • E-ducation (56)
  • Environmental (80)
  • Events (163)
  • Food (128)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (19)
  • Non-pharma applications (229)
  • Other industrial use (69)
  • Pharma applications (731)
  • Supramolecular systems (27)
  • Uncategorized (47)

Top Posts

  • The mechanism and therapy of aortic aneurysms
  • Lanosterol eye drops for cataract treatment
  • Alfa-cyclodextrin MS-signals from Danish Golden Age paintings
  • Website of EuroCD Conference is open
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • Crystallization inhibition by methylated cyclodextrin
  • Green materials with promising applications: Cyclodextrins-based deep eutectic supramolecular polymers
  • GRAS status of CD derivatives
  • Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated colitis in mice
  • Aggregation versus inclusion complexes to solubilize drugs with cyclodextrins. A case study using sulfobutylether-β-cyclodextrins and remdesivir

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 552 other subscribers
 

Loading Comments...